Developing cell-free biology for industrial applications



Although cell-free protein synthesis has been practiced for decades as a research tool, only recently have advances suggested its feasibility for commercial protein production. This focused review, based on the 2005 Amgen Award lecture, summarizes the relevant progress from the Swartz laboratory. When our program began, projected costs were much too high, proteins with disulfide bonds could not be folded effectively, and no economical scale-up technologies were available. By focusing on basic biochemical reactions and by controlling cell-free metabolism, these limitations have been methodically addressed. Amino acid supply has been stabilized and central metabolism activated to dramatically reduce substrate costs. Control of the sulfhydral redox potential has been gained and a robust disulfide isomerase added to facilitate oxidative protein folding. Finally, simple scale-up technologies have been developed. These advances not only suggest production feasibility for pharmaceutical proteins, they also provide enabling technology for producing patient-specific vaccines, for evolving new enzymes to enable biological hydrogen production from sunlight, and for developing new and highly effective water filters. Although many challenges remain, this newly expanded ability to activate and control protein production holds much promise for both research and commercial applications.


Cell-free biology Cell-free protein synthesis Metabolic engineering Cytomim Oxidative protein folding Cell-free scale-up 


  1. 1.
    Calhoun KA, Swartz JR (2005) An economical method for cell-free protein synthesis using glucose and nucleoside monophosphates. Biotechnol Prog 21:1146–1153CrossRefGoogle Scholar
  2. 2.
    Calhoun KA, Swartz JR (2005) Energizing cell-free protein synthesis with glucose metabolism. Biotechnol Bioeng 90:606–613CrossRefGoogle Scholar
  3. 3.
    Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R (1997) Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma—long term results of a clinical trial. Blood 89:3129–3135Google Scholar
  4. 4.
    Jewett MC, Swartz JR (2004) Mimicking the Escherichia coli cytoplasmic environment activates long-lived and efficient cell-free protein synthesis. Biotechnol Bioeng 86:119–126CrossRefGoogle Scholar
  5. 5.
    Kim RG, Choi CY (2000) Expression-independent consumption of substrates in cell-free expression system from Escherichia coli. J Biotechnol 84:27–32CrossRefGoogle Scholar
  6. 6.
    Kim DM, Swartz JR (2000) Oxalate improves protein synthesis by enhancing ATP supply in a cell-free system derived from Escherichia coli. Biotechnol Lett 22:1537–1542CrossRefGoogle Scholar
  7. 7.
    Kim DM, Swartz JR (2001) Regeneration of adenosine triphosphate from glycolytic intermediates for cell-free protein synthesis. Biotechnol Bioeng 74:309–316CrossRefGoogle Scholar
  8. 8.
    Kim DM, Swartz JR (2004) Efficient production of a bioactive, multiple disulfide-bonded protein using modified extracts of Escherichia coli. Biotechnol Bioeng 85:122–129CrossRefGoogle Scholar
  9. 9.
    Knapp K, Swartz JR (2004) Cell-free production of active E. coli thioredoxin reductase and glutathione reductase. FEBS Lett 559:66–70CrossRefGoogle Scholar
  10. 10.
    Liu D, Zawada J, Swartz JR (2005) Streamlining Escherichia coli S30 extract preparation for economical cell-free protein synthesis. Biotechnol Prog 21:460–465CrossRefGoogle Scholar
  11. 11.
    Michel-Reydellet N, Calhoun K, Swartz JR (2004) Amino acid stabilization for cell-free protein synthesis by modification of the E. coli genome. Metab Eng 86:19–26Google Scholar
  12. 12.
    Michel-Reydellet N, Woodrow K, Swartz J (2005) Increasing PCR fragment stability and protein yields in a cell-free system with genetically modified Escherichia coli extracts. J Mol Microbiol Biotechnol 9:26–34CrossRefGoogle Scholar
  13. 13.
    Narindrasorasak S, Bridger WA (1978) Probes of the structure of phosphoenol pyruvate synthetase: effects of a transition state analogue on enzyme conformation. Can J Biochem 56:816–819CrossRefGoogle Scholar
  14. 14.
    Nirenberg MW, Matthaei JH (1961) The dependence of cell-free protein synthesis in E.coli upon naturally occurring or synthetic polyribonucleotides. Proc Natl Acad Sci USA 47:1588–1602CrossRefGoogle Scholar
  15. 15.
    Posewitz MC, King PW, Smolinski SL, Zhang L, Seibert M, Ghirardi ML (2004) Discovery of two novel radical S-adenosylmethionine proteins required for the assembly of an active [Fe] hydrogenase. J Biol Chem 279:25711–2572CrossRefGoogle Scholar
  16. 16.
    Ryabova LA, Vinokurov LM, Shekhovtsova EA, Alakhov YB, Spirin AS (1995) Acetyl phosphate as an energy source for bacterial cell-free translation systems. Anal Biochem 226:184–186CrossRefGoogle Scholar
  17. 17.
    Tao MH, Levy R (1993) Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362:755–759CrossRefGoogle Scholar
  18. 18.
    Underwood K, Swartz JR, Puglisi JD (2005) Quantitative polysome analysis identifies limitations in bacterial cell-free protein synthesis. Biotechnol Bioeng 91:425–435CrossRefGoogle Scholar
  19. 19.
    Voloshin AM, Swartz JR (2005) Efficient and scalable method for scaling up cell-free protein synthesis systems in batch mode. Biotechnol Bioeng 91:516–521CrossRefGoogle Scholar
  20. 20.
    Yang J, Kanter G, Voloshin A, Levy R, Swartz JR (2004) Expression of active murine granulocyte-macrophage colony-stimulating factor in an Escherichia coli cell-free system. Biotechnol Prog 20:1689–1696CrossRefGoogle Scholar
  21. 21.
    Yang J, Kanter G, Voloshin A, Michel-Reydellet N, Velkeen H, Levy R, Swartz JR (2005) Rapid expression of vaccine proteins for B cell lymphoma in a cell-free system. Biotechnol Bioeng 89:503–511CrossRefGoogle Scholar
  22. 22.
    Yin G, Swartz JR (2004) Enhancing multiple disulfide-bonded protein folding in a cell-free system. Biotechnol Bioeng 86:188–195CrossRefGoogle Scholar
  23. 23.
    Zawada J, Swartz J (2005) Maintaining rapid growth in moderate-density Escherichia coli fermentations. Biotechnol Bioeng 89:407–415CrossRefGoogle Scholar

Copyright information

© Society for Industrial Microbiology 2006

Authors and Affiliations

  1. 1.Departments of Chemical Engineering and Bioengineering, Stauffer III, Rm 113Stanford UniversityStanfordUSA

Personalised recommendations